

(19)		Canadian Intellectual Property Office	Office de la Propriété Intellectuelle du Canada	(11) CA 2 412 181	(13) A1
		An Agency of Industry Canada	Un organisme d'Industrie Canada	(40) 09.12.2002 (43) 09.12.2002	

(12)

(21) 2 412 181

(51) Int. Cl 7: C07K 5/06, C07C 257/00,  
A61K 38/04

(22) 15.06.2001

(85) 09.12.2002

(86) PCT/EP01/06814

(87) WO01/096366

(30) 100 29 015.9 DE 15.06.2000

(72) SCHWEINITZ, ANDREA (DE).  
STEINMETZER, TORSTEN (DE).  
KUNZEL, SEBASTIAN (DE).  
STURZEBECHER, JORG (DE).

(71) CURACYTE AG,  
Gollerstr. 70  
80339, MUNCHEN, XX (DE).

(74) GOUDREAU GAGE DUBUC

(54) INHIBITEURS DU FACTEUR DE COAGULATION XA

(54) DIPEPTIDE INHIBITORS FOR THE BLOOD-CLOTTING FACTOR XA

(57)

The invention relates to derivatives of amidino-benzylamine, especially derivatives of 4-amidino-benzylamine, with two bonded amino acids. These derivatives represent a novel group of highly active and very selective F Xa- inhibitors for treating cardiovascular diseases and thrombotic events.



Office de la Propriété  
Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2412181 A1 2002/12/09

(21) 2 412 181

(12) DEMANDE DE BREVET CANADIEN  
CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2001/06/15

(87) Date publication PCT/PCT Publication Date: 2002/12/09

(85) Entrée phase nationale/National Entry: 2002/12/09

(86) N° demande PCT/PCT Application No.: EP 2001/006814

(87) N° publication PCT/PCT Publication No.: 2001/096366

(30) Priorité/Priority: 2000/06/15 (100 29 015.9) DE

(51) Cl. Int.<sup>7</sup>/Int.Cl.<sup>7</sup> C07K 5/06, A61K 38/04, C07C 257/00

(71) Demandeur/Applicant:

CURACYTE AG, DE

(72) Inventeurs/Inventors:

STURZEBECHER, JORG, DE;  
STEINMETZER, TORSTEN, DE;  
KUNZEL, SEBASTIAN, DE;  
SCHWEINITZ, ANDREA, DE

(74) Agent: GOUDREAU GAGE DUBUC

(54) Titre : INHIBITEURS DU FACTEUR DE COAGULATION XA

(54) Title: DIPEPTIDE INHIBITORS FOR THE BLOOD-CLOTTING FACTOR XA

(57) Abrégé/Abstract:

The invention relates to derivatives of amidino-benzylamine, especially derivatives of 4-amidino-benzylamine, with two bonded amino acids. These derivatives represent a novel group of highly active and very selective F Xa-inhibitors for treating cardiovascular diseases and thrombotic events.

Canada

<http://opic.gc.ca> • Ottawa-Hull K1A 0C9 • <http://cipa.gc.ca>

OPIC • CIPO 191

OPIC  CIPO

## (12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges Eigentum  
Internationales Büro(43) Internationales Veröffentlichungsdatum  
20. Dezember 2001 (20.12.2001)

PCT

(10) Internationale Veröffentlichungsnummer  
**WO 01/96366 A3**(51) Internationale Patentklassifikation<sup>7</sup>: C07K 5/06,  
A61K 38/04, C07C 257/00St.-Jacob-Str. 6, D-07743 Jena (DE). SCHWEINITZ,  
Andrea [DE/DE]; Gustav-Fischer-Str. 15, D-07745 Jena  
(DE).

(21) Internationales Aktenzeichen: PCT/EP01/06814

(74) Anwalt: BÖSL, Raphael; Bardehle, Pagenberg, Dost, Altenburg, Geissler, Innsbruck, Galileiplatz 1, 81679 München  
(DE).(22) Internationales Anmeldedatum:  
15. Juni 2001 (15.06.2001)(81) Bestimmungsstaaten (national): AU, BR, CA, CR, JP,  
NO, NZ, US, ZA.

(25) Einreichungssprache: Deutsch

(84) Bestimmungsstaaten (regional): europäisches Patent (AT,  
BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE, TR).

(26) Veröffentlichungssprache: Deutsch

(88) Veröffentlichungsdatum des internationalen  
Recherchenberichts: 25. April 2002(30) Angaben zur Priorität:  
100 29 015.9 15. Juni 2000 (15.06.2000) DE

Veröffentlicht:

— mit internationalem Recherchenbericht

(71) Anmelder (für alle Bestimmungsstaaten mit Ausnahme von  
US): CURACYTE AG [DE/DE]; Gollerstr. 70, 80339  
München (DE).Zur Erklärung der Zweibuchstaben-Codes und der anderen  
Abkürzungen wird auf die Erklärungen ("Guidance Notes on  
Codes and Abbreviations") am Anfang jeder regulären Ausgabe  
der PCT-Gazette verwiesen.

(72) Erfinder; und

(75) Erfinder/Anmelder (nur für US): STÜRZEBECHER,  
Jörg [DE/DE]; Huberstrasse 38, D-99094 Erfurt (DE).  
STEINMETZER, Torsten [DE/DE]; Ricarda-Huch-Weg  
23, D-07743 Jena (DE). KÜNZEL, Sebastian [DE/DE];**A3**

(54) Title: DIPEPTIDE INHIBITORS FOR THE BLOOD-CLOTTING FACTOR XA

(54) Bezeichnung: DIPEPTIDISCHE HEMMSTOFFE FÜR DEN GERINNUNGSFAKTO R XA

(57) Abstract: The invention relates to derivatives of amidino-benzylamine, especially derivatives of 4-amidino-benzylamine, with two bonded amino acids. These derivatives represent a novel group of highly active and very selective F Xa-inhibitors for treating cardiovascular diseases and thrombotic events.

**WO 01/96366**

(57) Zusammenfassung: Die Erfindung betrifft Derivate des Amidino-Benzylamins, insbesondere solche des 4-Amidino-benzylamins, mit zwei gebundenen Aminosäuren, die eine neue Gruppe von hochaktiven und sehr selektiven F Xa-Hemmstoffen zur Behandlung kardiovaskulärer Erkrankungen und thrombotischer Ereignisse darstellen.

## Inhibitors for the coagulation factor Xa

5 The invention relates to novel inhibitors for the coagulation factor Xa for the treatment of cardiovascular diseases and for the prevention of thromboembolic events.

10 The anticoagulants of the heparin type or the vitamin K antagonists presently employed clinically do not comply with all requirements for an "ideal" antithrombotic. Therefore alternatives are sought with low molecular weight inhibitors of the coagulation enzymes, especially of thrombin and factor Xa (F Xa). A 15 particular advantage of F Xa inhibitors in comparison with thrombin inhibitors could be the lower tendency to bleeding which has been shown in various animal experiments. Thus the bleeding time was only minimally influenced in antithrombotically effective doses (J. M. 20 Herbert et al., J. Pharmacol. Exp. Ther. 276, 1030-1038, 1996; K. Sato et al., Brit. J. Pharmacol. 123, 92-96, 1998).

25 The first nonpeptide compounds having a high affinity for F Xa were symmetrical bisbenzamidines ( $K_i = 13$  nM for the most active compound BABCH) (J. Stürzebecher et al., Thromb. Res. 54, 245-252, 1998). The naphthamidine derivative DX-9065a has two basic groups and inhibits F Xa selectively with  $K_i = 24$  nM (T. Hara et al., Thromb. 30 Haemost. 71, 314-319, 1994). The inhibitor YM-60828 (K. Sato et al., Eur. J. Pharmacol. 339, 141-146, 1997), which is structurally related to DX-9065a, is even more active ( $K_i = 1.3$  nM). In the meantime, a whole series 35 of further bis-basic compounds have been described in which, for example, two benzamidine residues are linked via an oxazoline ring ( $K_i = 18$  nM) (M.L. Quan et al., Bioorg. Med. Chem. Lett. 7, 2813-2818, 1997) or a carboxymethyl-alkyl chain ( $K_i = 34$  nM) (T.P. Maduskuie

- 2 -

et al., J. Med. Chem. 41, 53-62, 1998). The disadvantage of the bis-basic compounds is, in particular, the low bioavailability after oral administration.

5

Inhibitors for F Xa which only contain one basic group have also been described. N-substituted amidino-phenoxy pyridines ( $K_i = 0.11$  nM for BX-807834) were developed on the basis of BABCH (R. Mohan et al., 10 Bioorg. Med. Chem. Lett. 8, 1877-1882, 1998; G.B. Phillips et al., J. Med. Chem. 41, 3557-3562, 1998). Amides of  $\text{Na}$ -adamantyloxycarbonyl-3-amidinophenylalanine ( $K_i = 74$  nM for the most active compound) are selective inhibitors of F Xa (S. Sperl et al., Biol. 15 Chem. 381, 321-329, 2000), while  $\text{Na}$ -arylsulfonyl-aminoacylated esters of 3-amidinophenylalanine have a low inhibitory action ( $K_i \approx 840$  nM for TAPAM) (J. Stürzebecher et al., Thromb. Res. 54, 245-252, 1998). WO 96/10022 discloses inhibitors which no longer have 20 any strong charge at all ( $K_i = 3.0$  nM for the most active compound).

Until now, only a few peptides which are derived from the substrate sequence Ile-Glu-Gly-Arg have been 25 described as inhibitors of F Xa. The chloromethyl ketones described by Kettner and Shaw (Thromb. Res. 22, 645-652, 1981) inhibit F Xa irreversibly and are not suitable for in vivo applications. On the other hand, the peptides SEL 2489 ( $K_i = 25$  nM) and SEL 2711 ( $K_i = 3$  nM) are extremely active (J. A. Ostrem et al., 30 Biochemistry 37, 1053-1059, 1998). Some peptidyl arginine aldehydes have also been described which, in addition to argininal in the P1 position, have a D-arginine or an unnatural basic amino acid in P3 (Z.H. 35 Jonathan, Bioorg. Med. Lett. 9, 3459-3464, 1999). However, so far no peptidyl agmatine derivatives are known as inhibitors of F Xa, although this type of inhibitor has led to considerable advances in the further development of thrombin inhibitors. In this

- 3 -

case, the successes with compounds of the D-Phe-Pro-Arg type having a C-terminal agmatine and derivatives derived therefrom were particularly noteworthy. Picomolar  $K_i$  values were achieved for thrombin 5 inhibition and the oral bioavailability was improved (T.J. Tucker et al., J. Med. Chem. 40, 1565-1569 and 3687-3693, 1997). In this case, however, no inhibition of F Xa was observed. For instance, melagatran, which has a 4-amidinobenzylamine residue at the C terminus 10 and is very unspecific, inhibits F Xa with a  $K_i = 2.8 \mu\text{M}$ . On the other hand, trypsin ( $K_i = 4.0 \text{ nM}$ ) and thrombin ( $K_i = 2.0 \text{ nM}$ ) are inhibited more than three orders of magnitude more strongly (D. Gustafsson et al., Blood Coagul. Fibrinolysis 7, 69-79, 1996).

15

The invention is based on the object of specifying an active compound which is also suitable for therapeutic applications and inhibits the coagulation factor Xa with high activity and specificity and which can be 20 prepared with the lowest possible synthesis expenditure.

Surprisingly, it has been found that acylated amidinobenzylamine according to the general formula I 25 shown in Patent claim 1, in particular compounds of 4-amidinobenzylamine in which X, R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> result in natural and/or unnatural amino acids, inactivate factor Xa very efficaciously and selectively and effectively inhibit the coagulation of human blood plasma. 30 Amidinobenzylamine in this case forms a particularly active inhibitor of factor Xa if the amidino group is in the 4-position, glycine and D-serine tert-butyl ether are bonded as amino acids and if the compound has an N-terminal protective group R<sub>4</sub> composed of an aryl- 35 or aralkylsulfonyl residue.

Besides factor Xa, other enzymes were markedly less inhibited by the glycine derivatives, such that the derivatives of amidinobenzylamine according to the

- 4 -

invention are a novel group of highly active and very selective F Xa inhibitors. In contrast to this, compounds which carry no H as R<sub>1</sub> (e.g. alanine derivatives) no longer selectively inhibit factor Xa, 5 but are also strong inhibitors of trypsin, thrombin and plasmin.

The compounds are as a rule present as salts with mineral acids, preferably as hydrochlorides, or as 10 salts with suitable organic acids.

The compounds of the general formula I can be prepared in a manner known in principle, as described below:

15 The starting compound 4-cyanobenzylamine is prepared from 4-cyanobenzyl bromide via Gabriel synthesis (G. Wagner and I. Wunderlich, Pharmazie 32, 76-77, 1977; B.C. Bookser and T.C. Bruice, J. Am. Chem. Soc. 113, 4208-4218, 1991). The Boc-protected acetyloxamidino-20 benzylamine is obtained from the 4-cyanobenzylamine thus prepared. The coupling of the further amino acids and of the protective group R<sub>4</sub> is carried out by means of standard coupling methods using Boc as an N-terminal protective group. The second amino acid can also be 25 coupled directly as an N-aryl- or N-aralkylsulfonyl-protected amino acid. The peptide analogs are synthesized sequentially, beginning from the acetyloxamidinobenzylamine. Most of the products crystallize well and can thus be simply purified. The 30 purification of the inhibitors is carried out in the last stage by means of preparative, reversed-phase HPLC.

The invention will be illustrated in greater detail 35 below with the aid of three working examples:

- 5 -

Working example 1:

Synthesis of benzylsulfonyl-D-Ser(Bz)-Gly-4-amidino-benzylamide x HCl

5

1.1 Boc-4-cyanobenzylamide

20 g (0.151 mol) of 4-cyanobenzylamine were dissolved in 300 ml of H<sub>2</sub>O, 150 ml of dioxane and 150 ml of 1 N NaOH. 37.5 ml of di-tert-butyl dicarbonate were added dropwise with ice cooling and the mixture was stirred at 0°C for one hour and at room temperature for a further 24 hrs. The dioxane was removed i.v. and the aqueous residue was extracted 3 times with ethyl acetate. The combined extracts were washed 3 times with 5% strength KHSO<sub>4</sub> solution and 3 times with saturated NaCl solution, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated i.v. (white crystals). HPLC: acetonitrile/H<sub>2</sub>O, elution in 44.1% acetonitrile; yield: 30.48 g (0.131 mol), 87%.

20

1.2 Boc-4-acetyloxamidinobenzylamide

According to Judkins et al. (Synthetic Comm. 26, 4351-4367, 1996), 30.48 g (0.131 mol) of Boc-4-cyanobenzylamide were dissolved in 300 ml of abs. ethanol with 13.65 g (0.197 mol) of hydroxylamine x HCl and 34 ml (0.197 mol) of DIEA. The solution was refluxed for 2 hrs and stirred at room temperature overnight. The batch was then concentrated i.v., the residue was dissolved in about 200 ml of acetic acid and the solution was treated with 18.67 ml (0.197 mol) of acetic anhydride. After 1 hr, it was again concentrated, dissolved in ethyl acetate and washed 3 times each with 5% strength KHSO<sub>4</sub> solution and saturated NaCl solution at 0°C. After drying over Na<sub>2</sub>SO<sub>4</sub> and concentrating i.v., a white powder precipitated. HPLC: acetonitrile/H<sub>2</sub>O, elution in 32.0% acetonitrile; yield: 31.3 g (0.102 mol) 78%.

- 6 -

1.3 4-Acetyloxamidinobenzylamine x HCl

5 mmol of Boc-4-acetyloxamidinobenzylamide are dissolved in 20 ml of 1 N HCl in glacial acetic acid 5 and the solution is allowed to stand at room temperature for 45 min. It is then largely concentrated i.v., and the product is precipitated using dry diethyl ether, filtered off on a frit, washed again with fresh ether and dried i.v. On account of the quantitative 10 reaction, the product was employed for the next synthesis step without further purification.

1.4 Boc-Gly-4-acetyloxamidinobenzylamide

15 The coupling of Boc-Gly-OH (Orpegen, Heidelberg) to 4-acetyloxamidinobenzylamine was carried out according to Frérot et al. (Tetrahedron 47, 259 ff., 1991). To this end, 2.064 g (9.3 mmol) of 4-acetyloxamidinobenzylamine x HCl and 1.629 g (9.3 mmol) of Boc-Gly-OH were 20 dissolved in about 25 ml of DMF. 4.84 g (9.3 mmol) of PyBOP and 3.878 ml (27.9 mmol) of TEA were then added at 0°C and the pH was adjusted to 9 using TEA. After stirring at room temperature for 1 hr, the mixture was concentrated i.v., taken up in ethyl acetate and 25 subjected to acidic, basic and neutral washing 3 times each, dried and concentrated. Yield: 3 g (8.2 mmol) 88%.

1.5 Boc-Gly-4-amidinobenzylamide x AcOH

30

3 g (8.2 mmol) of Boc-Gly-4-acetyloxamidinobenzylamide were dissolved in 200 ml of 90% strength acetic acid. 300 mg of 10% palladium on activated carbon were then added under argon. Argon was replaced by a hydrogen 35 atmosphere and the batch was hydrogenated for 24 hrs with vigorous stirring. The catalyst was filtered off and the filtrate was concentrated i.v.. Yield: 2.9 g (7.9 mmol) 96%.

- 7 -

1.6 H-Gly-4-amidinobenzylamide x 2 HCl

2.9 g (7.9 mmol) of Boc-Gly-4-amidinobenzylamide were dissolved in 100 ml of 1 N HCl in glacial acetic acid 5 and the solution was allowed to stand at room temperature for 45 min. It was then largely concentrated i.v. and precipitated using dry diethyl ether, then filtered off on a frit and the product was again washed with fresh ether. After drying the product 10 i.v., it was used without further purification for the synthesis according to item 1.8.

1.7 Benzylsulfonyl-D-Ser(Bz)-OH

15 229 mg (1.173 mmol) of H-D-Ser(Bz)-OH and 408  $\mu$ l (2.345 mmol) of DIEA were dissolved in 50 ml of 50% acetonitrile. 335 mg (1.76 mmol) of benzylsulfonyl chloride were then added and the mixture was stirred at room temperature for 12 hrs. It was concentrated i.v., 20 taken up using ethyl acetate and subjected to acidic and neutral washing 3 times each. After drying over sodium sulfate, it was concentrated i.v. Yield: 289 mg (0.827 mmol) 71%.

25 1.8 Benzylsulfonyl-D-Ser(Bz)-Gly-4-amidinobenzylamide x TFA

30 151 mg (0.433 mmol) of benzylsulfonyl-D-Ser(Bz)-OH and 121 mg (0.433 mmol) of H-Gly-4-amidinobenzylamide x 2 HCl were dissolved in a little abs. DMF. 225 mg (0.433 mmol) of PyBOP and 230  $\mu$ l (1.32 mmol) of DIEA 35 were added with ice cooling. After stirring at room temperature for 1 hr, the mixture was concentrated i.v. and the product was purified by means of HPLC (acetonitrile/H<sub>2</sub>O, 0.1% trifluoroacetic acid, elution in 37.4% acetonitrile). Yield: 232 mg (0.356 mmol) 82%.

- 8 -

Working example 2:

Inhibition of F Xa by selected compounds having Y = amidino

5

R <sub>4</sub>	R <sub>3</sub> con- figura- tion	R <sub>3</sub>	R <sub>2</sub>	X-R <sub>1</sub>	Amidino position	K <sub>b</sub> $\mu$ M
H	L	CH <sub>2</sub> -OH	H	CH <sub>2</sub>	4	> 1000
Boc	L	CH <sub>2</sub> -OH	H	CH <sub>2</sub>	4	110
H	D	CH <sub>2</sub> -OH	H	CH <sub>2</sub>	4	> 1000
Ac	D	CH <sub>2</sub> -OH	H	CH <sub>2</sub>	4	> 1000
Bz-SO <sub>2</sub>	D	CH <sub>2</sub> -OH	H	CH <sub>2</sub>	4	3.0
Bz-SO <sub>2</sub>	D	CH <sub>2</sub> -O- Bz	H	CH <sub>2</sub>	4	0.050
Bz-SO <sub>2</sub>	D	CH <sub>2</sub> -O- tBu	H	CH <sub>2</sub>	4	0.030
Bz-SO <sub>2</sub>	D	CH <sub>2</sub> -O- tBu	H	CH <sub>2</sub> -CH <sub>3</sub>	4	0.044
H	D	CH <sub>2</sub> -O- Bz	H	CH <sub>2</sub>	3	140
Boc	D	CH <sub>2</sub> -O- Bz	H	CH <sub>2</sub>	3	93
Bz-SO <sub>2</sub>	D	CH <sub>2</sub> -O- Bz	H	CH <sub>2</sub>	3	84

Determination of the inhibitory action

For the determination of the inhibitory action, 200  $\mu$ l of tris buffer (0.05 M, 0.154 M NaCl, 5% ethanol, pH 8.0; contains the inhibitor), 25  $\mu$ l of substrate (Moc-D-Nle-Gly-Arg-pNA in H<sub>2</sub>O; Pentapharm Ltd., Basle, Switzerland) and 50  $\mu$ l of F Xa (from Rind, Diagnostic Reagents Ltd, Thame, GB) were incubated at 25°C. After 10 3 min, the reaction was interrupted by addition of 25  $\mu$ l of acetic acid (50%) and the absorption at 405 nm was determined by means of microplate reader (MR 5000, Dynatech, Denkendorf, Germany). The K<sub>i</sub> values were 15

- 9 -

determined according to Dixon (Biochem. J. 55, 170-171, 1953) by linear regression by means of a computer program. The  $K_1$  values are the mean of at least three determinations.

5

Working example 3:

Inhibition of the coagulation of human plasma by benzylsulfonyl-D-Ser(Bz)-Gly-4-amidinobenzylamide

10

Concentration μM	Prolongation of the <u>coagulation</u> time (%)	
	aPTT	PT
3.3	385	386
1.7	260	266
0.83	185	198
0.42	146	153
0.21	122	127
0.1	111	119

Determination of the inhibition of coagulation

15 For the determination of the prothrombin time (PT), 100  $\mu$ l of thromboplastin (Dade, Unterschleißheim) and 100  $\mu$ l of inhibitor, dissolved in  $\text{CaCl}_2$  (0.05 M, 5% ethanol) were incubated at 37°C for 2 min and the coagulation was started by addition of 100  $\mu$ l of human citrate plasma. For the determination of the activated partial thromboplastin time (aPTT), 100  $\mu$ l of human citrate plasma were incubated with 100  $\mu$ l of aPTT reagent (Roche Diagnostics, Mannheim) at 37°C for 3 min and the coagulation was started by addition of 100  $\mu$ l of inhibitor, dissolved in  $\text{CaCl}_2$  (0.05 M, 5% ethanol). The coagulation times were determined using the Thrombotrack coagulometer (Immuno, Heidelberg).

20


25

Abbreviations used:

	Ac	acetyl
	Boc	tert-butyloxycarbonyl
5	Bz	benzyl
	DIEA	diisopropylethylamine
	DMF	N,N-dimethylformamide
	i.v.	in vacuo
10	PyBOP	benzotriazol-1-yl-N-oxytris- (pyrrolidino)phosphonium hexafluorophosphate
	TEA	triethylamine
15	TFA	trifluoroacetic acid
	THF	tetrahydrofuran
	tBu	tert-butyl

## Patent claims

1. Inhibitors for the coagulation factor Xa of the  
5 general formula I:



in which the substituent Y occurs in the 3- or 4-  
10 position and is an amidino group



in which R<sub>6</sub> has an H, an OH or a carbonyl residue -CO-R  
15 or oxycarbonyl residue -COO-R, where R can be a  
branched or unbranched alkyl having 1-16 C atoms, a  
substituted or unsubstituted aryl or heteroaryl residue  
or a substituted or unsubstituted aralkyl or  
heteroaralkyl residue,

20

X is a CH group or N,

R<sub>1</sub> is H or a branched or unbranched alkyl having 1-8 C  
atoms or (CH<sub>2</sub>)<sub>n</sub>-OH where n = 1-5,

25

R<sub>2</sub> is an H or a branched or unbranched alkyl having 1-8  
C atoms,

30

R<sub>3</sub> is a branched or unbranched alkyl having 1-8 C atoms  
or a (CH<sub>2</sub>)<sub>n</sub>-O-R<sub>6</sub>, (CH<sub>2</sub>)<sub>n</sub>-S-R<sub>6</sub> or (CH<sub>2</sub>)<sub>n</sub>-NH-R<sub>6</sub> where n = 1-  
5 and R<sub>6</sub> is a branched or unbranched alkyl having 1-16  
C atoms, a substituted or unsubstituted aryl or  
heteroaryl residue or a substituted or an unsubstituted  
aralkyl or heteroaralkyl residue and

- 12 -

R<sub>4</sub> is a sulfonyl residue -SO<sub>2</sub>-R, a carbonyl residue -CO-R, an oxycarbonyl residue -COO-R or an H, where R is a branched or unbranched alkyl having 1-16 C atoms, a substituted or an unsubstituted aryl or heteroaryl residue, a substituted or unsubstituted aralkyl or heteroaralkyl residue, an adamantyl residue, a camphor residue or a cyclohexylmethyl residue.

2. Inhibitors according to Claim 1, characterized in  
10 that, in the amidinobenzylamide, the amidino group is  
in the 4-position and that the amino acids Gly and D-  
Ser(tBu) and, as R<sub>4</sub>, an aryl or an aralkylsulfonyl  
residue are bonded thereto.

15 3. Use of the inhibitors according to Claim 1 for the  
preparation of orally, subcutaneously, intravenously or  
transdermally administrable medicaments for the  
prevention or treatment of thromboembolic diseases.

20 4. Use according to Claim 3, characterized in that  
the inhibitors are employed as medicaments in the form  
of tablets, coated tablets, capsules, pellets,  
suppositories, solutions or patches, etc.

25 5. Use of the inhibitors according to Claim 1 as a  
diagnostic agent, in particular in thrombotic events.